Albireo Pharma Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
ALBO Nasdaq 8731 http://www.albireopharma.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Albireo Pharma Inc

Albireo Presents New Bylvay® (odevixibat) Data at Annual ESPGHAN Congress - Jun 24th, 2022 12:30 pm
Albireo Announces Presentation of New Data in Pediatric and Adult Liver Diseases - Jun 23rd, 2022 12:30 pm
Albireo to Present New Data at the EASL International Liver Congress™ 2022 - Jun 8th, 2022 12:30 pm
Albireo to Present New Data at the 54th Annual Meeting of ESPGHAN - Jun 7th, 2022 12:30 pm
Albireo to Participate at Upcoming Investor Conferences - Jun 2nd, 2022 8:30 pm
Albireo Presented Data in Cholestatic Liver Diseases at Digestive Disease Week (DDW) 2022 - May 23rd, 2022 12:30 pm
Time To Worry? Analysts Are Downgrading Their Albireo Pharma, Inc. (NASDAQ:ALBO) Outlook - May 21st, 2022 12:11 pm
Albireo to Participate in the H.C. Wainwright Global Investment Conference 2022 - May 19th, 2022 8:30 pm
Albireo Pharma (ALBO) Reports Q1 Loss, Lags Revenue Estimates - May 16th, 2022 9:15 pm
Albireo Reports Q1 2022 Financial Results and Business Update - May 16th, 2022 8:01 pm
Here's What Albireo Pharma, Inc.'s (NASDAQ:ALBO) Shareholder Ownership Structure Looks Like - May 15th, 2022 12:52 pm
Exelixis (EXEL) Tops Q1 Earnings Estimates - May 10th, 2022 9:25 pm
Albireo to Report Q1 2022 Financial Results on May 16 - May 9th, 2022 12:30 pm
10 Biotech Stocks to Buy Today According to Kerr Neilson’s Platinum Asset Management - Apr 20th, 2022 6:25 pm
Investing in Albireo Pharma (NASDAQ:ALBO) five years ago would have delivered you a 57% gain - Apr 19th, 2022 10:13 am
10 Pharmaceutical Stocks to Buy Now According to Billionaire Kerr Neilson - Apr 14th, 2022 2:06 pm
Albireo Completes Enrollment in Pivotal Phase 3 ASSERT Study of BylvayTM (odevixibat) in Alagille Syndrome - Mar 29th, 2022 12:30 pm
Here's Why Albireo Pharma (NASDAQ:ALBO) Can Manage Its Debt Despite Losing Money - Mar 5th, 2022 12:07 pm
Albireo Pharma (ALBO) Reports Q4 Loss, Tops Revenue Estimates - Mar 1st, 2022 3:25 pm
Albireo Reports Q4 and Year-End 2021 Financial Results and Business Update - Mar 1st, 2022 1:30 pm